Bellicum Pharmaceuticals (NASDAQ:BLCM)‘s stock had its “overweight” rating reaffirmed by Cantor Fitzgerald in a note issued to investors on Wednesday, MarketBeat.com reports. They presently have a $18.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $10.00. Cantor Fitzgerald’s price target indicates a potential upside of 100.45% from the company’s current price.
A number of other analysts also recently commented on BLCM. Zacks Investment Research downgraded Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, January 12th. BidaskClub raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 4th. ValuEngine downgraded Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Wells Fargo downgraded Bellicum Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.00 price objective on the stock. in a research note on Wednesday, January 31st. Finally, Citigroup boosted their price objective on Bellicum Pharmaceuticals from $24.00 to $27.00 and gave the stock a “hold” rating in a research note on Friday, February 16th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. Bellicum Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $17.98.
Shares of BLCM traded up $0.74 during midday trading on Wednesday, reaching $8.98. The stock had a trading volume of 2,877,346 shares, compared to its average volume of 885,418. Bellicum Pharmaceuticals has a 52 week low of $5.02 and a 52 week high of $14.49. The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.37 and a current ratio of 8.37. The company has a market capitalization of $276.63, a PE ratio of -3.16 and a beta of 0.47.
In other news, major shareholder Bros. Advisors Lp Baker sold 260,600 shares of Bellicum Pharmaceuticals stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $8.63, for a total transaction of $2,248,978.00. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 18.77% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Schwab Charles Investment Management Inc. grew its holdings in shares of Bellicum Pharmaceuticals by 47.1% during the third quarter. Schwab Charles Investment Management Inc. now owns 131,217 shares of the biopharmaceutical company’s stock valued at $1,516,000 after buying an additional 41,995 shares in the last quarter. Virtus Fund Advisers LLC purchased a new position in shares of Bellicum Pharmaceuticals during the fourth quarter valued at $343,000. X Square Capital LLC purchased a new position in shares of Bellicum Pharmaceuticals during the fourth quarter valued at $544,000. Point72 Asset Management L.P. purchased a new position in shares of Bellicum Pharmaceuticals during the third quarter valued at $4,723,000. Finally, Prosight Management LP purchased a new position in shares of Bellicum Pharmaceuticals during the fourth quarter valued at $2,534,000. Institutional investors and hedge funds own 54.57% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://dakotafinancialnews.com/2018/04/12/bellicum-pharmaceuticals-blcm-pt-set-at-18-00-by-cantor-fitzgerald.html.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.